A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial

Fertility and Sterility

Volumn 107, Issue 5, 2017, Pages 1238-1245

  Zethraeus, Niklas ^a   Dreber, Anna ^b   Ranehill, Eva ^c,d   Blomberg, Liselott ^e   Labrie, Fernand ^f   von Schoultz, Bo ^d,e   Johannesson, Magnus ^b   Hirschberg, Angelica Lindén ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITÉ LAVAL   (Canada)

Author keywords

Depression; oral contraceptives; quality of life; randomized clinical trial; well being

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ORAL CONTRACEPTIVE AGENT;

ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HORMONE DETERMINATION; HUMAN; INCREASED APPETITE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MOOD; ORAL CONTRACEPTION; PANIC; PRIORITY JOURNAL; PSYCHOLOGICAL GENERAL WELL BEING INDEX; PSYCHOLOGICAL WELLBEING ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF CONTROL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WELLBEING; ADOLESCENT; ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH STATUS; INCIDENCE; PATIENT PREFERENCE; PLACEBO EFFECT; PREGNANCY; PSYCHOLOGY; REFERENCE VALUE; STATISTICS AND NUMERICAL DATA; SWEDEN; WOMEN'S HEALTH; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; DEPRESSION; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH STATUS; HUMANS; INCIDENCE; PATIENT PREFERENCE; PLACEBO EFFECT; PREGNANCY; REFERENCE VALUES; SWEDEN; TREATMENT OUTCOME; WOMEN'S HEALTH; YOUNG ADULT;

EID: 85017517297     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2017.02.120     Document Type: Article

References (34)

1. 1 Brynhildsen, J., Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf 5 (2014), 201–213.
2. 2 Potter, L., Oakley, D., de Leon-Wong, E., Cañamar, R., Measuring compliance among oral contraceptive users. Fam Plann Perspect 28 (1996), 154–158.
3. 3 Josefsson, A., Wiréhn, A.-B., Lindberg, M., Foldemo, A., Brynhildsen, J., Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010. BMJ Open, 3, 2013, e003401.
4. 4 Sanders, S.A., Graham, C.A., Bass, J.L., Bancroft, J., A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64 (2001), 51–58.
5. 5 Ott, M.A., Shew, M.L., Ofner, S., Tu, W., Fortenberry, J.D., The influence of hormonal contraception on mood and sexual interest among adolescents. Arch Sex Behav 37 (2008), 605–613.
6. 6 Hall, K.S., O'Connell White, K., Rickert, V.I., Reame, N., Westhoff, C., Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. Contraception 86 (2012), 518–525.
7. 7 Ernst, U., Baumgartner, L., Bauer, U., Janssen, G., Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation. Eur J Contracept Reprod Health Care 7 (2002), 238–243.
8. 8 Kelly, S., Davies, E., Fearns, S., McKinnon, C., Carter, R., Gerlinger, C., et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women. Clin Drug Investig 30 (2010), 325–336.
9. 9 Poromaa, I.S., Segebladh, B., Adverse mood symptoms with oral contraceptives. Acta Obstet Gynecol Scand 91 (2012), 420–427.
10. 10 Graham, C.A., Sherwin, B.B., The relationship between mood and sexuality in women using oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 18 (1993), 273–281.
11. 11 Graham, C.A., Ramos, R., Bancroft, J., Maglaya, C., Farley, T.M., The effects of steroidal contraceptives on the we1l-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 52 (1995), 363–369.
12. 12 O'Connell, K., Davis, A.R., Kerns, J., Oral contraceptives: side effects and depression in adolescent girls. Contraception 75 (2007), 299–304.
13. 13 Gingnell, M., Engman, J., Frick, A., Moby, L., Wikström, J., Fredrikson, M., et al. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill–—a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. Psychoneuroendocrinology 38 (2013), 1133–1144.
14. 14 Cullberg, J., Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with a placebo. Acta Psychiatr Scand Suppl 236 (1972), 1–86.
15. 15 Skovlund, C.W., Mørch, L.S., Kessing, L.V., Lidegaard, Ø., Association of hormonal contraception with depression. JAMA Psychiatry 73 (2016), 1154–1162.
16. 16 Chassany, O., Dimenäs, E., Dubois, D., Wu, A., Dupuy, H., The Psychological General Well-Being Index (PGWBI) user manual. 2004, MAPI Research Institute, Lyon, France.
17. 17 Beck, A.T., Steer, R.A., Ball, R., Ranieri, W.F., Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67 (1996), 588–597.
18. 18 Lundgren-Nilsson, Å., Jonsdottir, I.H., Ahlborg, G. Jr., Tennant, A., Construct validity of the psychological general well-being index (PGWBI) in a sample of patients undergoing treatment for stress-related exhaustion: a Rasch analysis. Health Qual Life Outcomes, 11, 2013, 2.
19. 19 Ke, Y., Bertin, J., Gonthier, R., Simard, J.N., Labrie, F., A sensitive, simple and robust LC–MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum. J Steroid Biochem Mol Biol 144 (2014), 523–534.
20. 20 Södergård, R., Bäckström, T., Shanbag, V., Carstensen, H., Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16 (1982), 801–810.
21. 21 Cohen, J., Statistical power analysis for the behavioral sciences. 2nd ed., 1988, Lawrence Erlbaum Associates, Mahwah: NJ.
22. 22 Shifren, J.L., Braunstein, G.D., Simon, J.A., Casson, P.R., Buster, J.E., Redmond, G.P., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343 (2000), 682–688.
23. 23 Somboonporn, W., Davis, S., Seif, M.W., Bell, R., Testosterone for peri and postmenopausal women. Cochrane Database Syst Rev, 2005, CD004509.
24. 24 Compagnone, N.A., Mellon, S.H., Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 21 (2000), 1–56.
25. 25 Simoncini, T., Genazzani, A.R., Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148 (2003), 281–292.
26. 26 Turkmen, S., Bäckstrom, T., Wahlstrom, G., Andreen, L., Johansson, I.M., Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol 162 (2011), 311–327.
27. 27 Rapkin, A.J., Akopians, A.L., Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder. Menopause Int 18 (2012), 52–59.
28. 28 Bäckström, T., Bixo, M., Johansson, M., Nyberg, S., Ossewaarde, L., Ragagnin, G., et al. Allopregnanolone and mood disorders. Prog Neurobiol 113 (2014), 88–94.
29. 29 Joffee, H., Cohen, L.S., Harlow, B.L., Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 (2003), 1523–1530.
30. 30 Lidegaard, O., Hougaard Nielsen, L., Wessel Skovlund, C., Lokkegaard, E., Venous thromobosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ, 344, 2012, e2990.
31. 31 Kurshan, N., Epperson, C.N., Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Womens Ment Health 9 (2006), 1–14.
32. 32 Caruso, S., Sareri, M.I., Agnello, C., Romano, M., Lo Presti, L., Malandrino, C., et al. Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 mg ethinyl estradiol. J Sex Med 8 (2011), 1478–1485.
33. 33 Zethraeus, N., Dreber, A., Ranehill, E., Blomberg, L., Labrie, F., von Schoultz, B., et al. Combined oral contraceptives and sexual function in women–a double-blind, randomized, placebo-controlled Trial. J Clin Endocrinol Metab 101 (2016), 4046–4053.
34. 34 Lopez, L.M., Kaptein, A.A., Helmerhorst, F.M., Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012, CD006586.